A recent study published in the New England Journal of Medicine has found that the experimental drug Iniparib could prove invaluable in treating triple-negative breast cancer. Researchers have found that the drug shrank tumors and slowed their rate of progress which is a hopeful sign for those who have been diagnosed, according to HealthDay News
"We were surprised [at the results] because triple-negative breast cancer is very difficult to treat," said study lead author Dr. Joyce O'Shaughnessy. "The big, big surprise was survival," she told the news source.
Most triple-negative breast cancers are treatable in early stages, but when they become metastatic, they can be difficult to contain. This form of breast cancer lacks estrogen and progesterone receptors in conjunction with a dearth of the protein HER2. Most conventional treatment options target these areas so they remain largely ineffective.
In clinical trials, women receiving Iniparib lived an average of 12.3 months as opposed to 7.7 months with chemotherapy treatment. The trials are still in the early stages, but the results look hopeful for patients and families.
According to BreastCancer.org, over 2.5 million breast cancer survivors currently live in the United States.